Skip to main content

Challenges and progress in childhood tuberculosis

© Flickr Marion Doss CC BY-SA 2.0Guest edited by Professor Ben Marais (University of Sydney, Australia), this series of articles provides an overview of the global child tuberculosis burden and examines issues such as diagnosis, advances in treatment, and novel vaccination approaches. The series aims to address the needs of researchers, clinicians and other individuals who require up-to-date information on this topic.

Pneumonia is pleased to be still accepting submissions for this thematic series.

Read more

Featured review: The role of co-infections and secondary infections in patients with COVID-19

New Content ItemThis review describes varying rates of co-infections and/or superinfections in patients with COVID-19 infections, although often a clear distinction between the two is not clear in the literature. When they occur, these infections appear to be associated with both severity of COVID-19 as well as poorer outcomes.

Read the article 


Aims and scope

Pneumonia is the only journal to focus exclusively on pneumonia. Publishing original research, case reports, reviews, commentaries and correspondence, Pneumonia provides an international forum for the exchange of knowledge by scientists and clinicians involved in studying the etiology and pathogenesis of pneumonia, as well as its diagnosis, epidemiology, treatment and prevention. The journal's scope extends to research on lung infections and diagnosis, inflammation and immunity, microbial pathogenesis and viral-bacterial interactions.

Cutting-edge research, insightful reviews and dedication to the community make Pneumonia an essential resource for clinicians, researchers, respirologists and allied professionals involved with infectious diseases.

Pneumonia archive

Pneumonia transferred to BioMed Central from Griffith University ePress in January 2016.
The archive of the journal has been transferred to a new platform and all articles previously published in the journal can be accessed here.

Latest Tweets

Your browser needs to have JavaScript enabled to view this timeline

Sign up to receive article alerts

Pneumonia is published continuously online-only. We encourage you to sign up to receive free email alerts to keep up to date with all of the latest articles by registering here.

Editors' profiles

Stephen Pelton

New Content ItemProfessor Stephen I. Pelton is Professor of Pediatrics and Epidemiology at Boston University Schools of Medicine and Public Health in Massachusetts. He is also former Director of Pediatric Infectious Diseases at Boston Medical Center (BMC) and current Coordinator of Pediatric AIDS Program. Professor Pelton is an active clinician, investigator, a member of the Boston Medical University Campus Institutional Review Board, and mentor for trainees in Pediatric Infectious Diseases.  He is principal investigator for the International Maternal Pediatric Adolescent AIDS Clinical Trials program (IMPAACT) at BMC that seeks to evaluate new strategies for prevention and treatment of HIV in children and adolescents. His laboratory is focused on vaccine-preventable diseases, especially those due to Streptococcus pneumoniae and new vaccines for prevention of respiratory tract infection due to nontypeable Haemophilus influenzae. Professor Pelton’s work has led to his recognition as a leading clinical scientist in studies of the impact of pneumococcal conjugate vaccine on invasive and respiratory tract disease in children.  He has been named as one of Boston’s top Pediatric Infectious Diseases physicians by Boston Magazine for the past 5 years (2012–2017).


Ger Rijkers

New Content ItemProfessor Ger Rijkers, co-Editor-in-Chief, has studied the interaction between Streptococcus pneumoniae and the human immune system for most of his professional career. Being a biologist and medical immunologist by training, and working in hospital laboratories, his focus of research has been the cellular and molecular mechanisms of the immune response during infection and following vaccination. Special attention is given to the major risk groups: the young, the old, and the immunocompromised. He has published widely in the peer-reviewed literature, has presented at a great number of international scientific and medical conferences and has supervised many PhD students in their research. Professor Rijkers joined the Laboratory of Medical Microbiology and Immunology of the St Antonius Hospital in Nieuwegein, The Netherlands in 2006. As of 2012 he has been head of the Science Department of University College Roosevelt, Middelburg, The Netherlands.

Annual Journal Metrics

  • Speed
    45 days to first decision for all manuscripts
    135 days to first decision for reviewed manuscripts only
    172 days from submission to acceptance
    38 days from acceptance to publication

    247,185 Downloads (2021)
    162 Altmetric mentions